ClinicalTrials.gg
CompletedNCT00232661Updated Feb 3, 2010

PROACT - Pre-Operative Arimidex Compared To Tamoxifen

A Phase 3 interventional study of ARIMIDEX (anastrazole) and NOLVADEX (tamoxifen) in Breast Cancer, sponsored by AstraZeneca. Completed at 79 sites in 10 countries. Open to female participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2010-02-03.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
452
Allocation
Randomized
Ages
60 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 111 studies testing anastrozole in Breast Neoplasms — 17 open to participants now, 28 under way, 10 of them phase 3. Anastrozole · Breast Neoplasms.

Enrollment
26th of 109
452 · median 148
Started
2000
with 1 other
Phase 3
38 of 111
5 open now
Registered
9th of 111
by date
Lead sponsor
16 of 111
AstraZeneca

Among the 111 studies testing anastrozole in Breast Neoplasms, this one is the 26th largest by enrollment of the 109 interventional ones that give a count, is one of 2 that started in 2000, is one of 38 in phase 3, and was the 9th registered.

Breast Neoplasms

14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

17 of the 111 studies testing anastrozole in Breast Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About anastrozole

Anastrozole: first FDA approval 1995 (ARIMIDEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,398 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 590 (25%) stop at 75 or younger; 103 take children under 18; 213 take healthy volunteers.

This study: 60 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies testing anastrozole in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to compare tamoxifen, versus a newer treatment, ARIMIDEX, which we already know to be well tolerated. The main objectives of this research study are to see whether using these drugs will shrink down tumours before surgery and to see if any shrinkage in the tumour affects the extent of surgery that is required.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Operable or potentially operable breast cancer
  • Invasive breast cancer proven to be hormone-sensitive (ER+/PR+)
  • Patients who might benefit from endocrine treatment prior to surgery
  • Signed written

Exclusion criteria

Exclusion Criteria:

  • Inoperable breast cancer
  • Patient unwilling to undergo surgery
  • Any reason why the patient may not be able to conform to study requirements
  • Any previous treatment for breast cancer
  • Previous Tamoxifen use as a part of breast cancer prevention trials
  • Not willing to stop taking drugs that affect sex-hormones such as HRT
  • Previous history of breast cancer
  • Previous history of invasive within the last 10 years
  • Any other severe disease that may prevent surgery, place the patient at risk, or influence the study results
  • Treatment with an experimental drug within the last 3 months
  • Risk of transmitting , or C
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
452 participants (actual)
06

What researchers measure

Primary outcomes

  1. Objective tumour response

    Time frame: Assessed at 3 months

Secondary outcomes

  1. Pathological response

    Time frame: Assessed at 3 months

  2. Extent of breast surgery

    Time frame: Assessed at 3 months

  3. Extent of axillary down-staging

    Time frame: Assessed at 3 months

  4. Clinical ultrasound response versus clinical caliper response

    Time frame: Assessed at 3 months

  5. Safety

    Time frame: Assessed up to 5 years + 30 days

  6. Complications due to surgery

    Time frame: Assessed up to 30 days post-surgery

  7. Health economics outcomes

    Time frame: Assessed up to 30 days post-surgery

  8. Quality of Life assessments

    Time frame: Assessed at 3 months

  9. Effect of ethnicity with respect to baseline patient and tumour characteristics, safety and objective tumour response rate

    Time frame: Assessed up to 5 years + 30 days

  10. Recurrence-free survival and survival

    Time frame: Assessed up to 5 years

07

Study locations

79 sites
  • Research Site
    Santa Rosa, California, United States
  • Research Site
    New Britain, Connecticut, United States
  • Research Site
    Torrington, Connecticut, United States
  • Research Site
    Springfield, Illinois, United States
  • Research Site
    Mason City, Iowa, United States
  • Research Site
    Baton Rouge, Louisiana, United States
  • Research Site
    Pittsfield, Massachusetts, United States
  • Research Site
    St. Louis, Missouri, United States
  • Research Site
    Albuquerque, New Mexico, United States
  • Research Site
    Portland, Oregon, United States
  • Research Site
    Austin, Texas, United States
  • Research Site
    Houston, Texas, United States
  • Research Site
    Olympia, Washington, United States
  • Research Site
    Antwerpen, Belgium
  • Research Site
    Hasselt, Belgium
  • Research Site
    Leuven, Belgium
  • Research Site
    Liege, Belgium
  • Research Site
    Rio de Janeiro, RJ, Brazil
  • Research Site
    Porto Alegre, RS, Brazil
  • Research Site
    São Paulo, SP, Brazil
  • Research Site
    Fortaleza, Brazil
  • Research Site
    Porto Alegre, Brazil
  • Research Site
    Sheffield, Brazil
  • Research Site
    Edmonton, Alberta, Canada
  • Research Site
    Newmarket, Ontario, Canada
  • Research Site
    Chicoutimi, Quebec, Canada
  • Research Site
    Montreal, Quebec, Canada
  • Research Site
    Quebec, Canada
  • Research Site
    Brno, Czech Republic
  • Research Site
    Nova Ves Pod Plesi, Czech Republic
  • Research Site
    Olomouc, Czech Republic
  • Research Site
    Peské Budjovice, Czech Republic
  • Research Site
    Praha 2, Czech Republic
  • Research Site
    Praha-5, Czech Republic
  • Research Site
    Lyon, Cedex 08, France
  • Research Site
    Avignon, France
  • Research Site
    Dijon, France
  • Research Site
    Limoges, France
  • Research Site
    Lyon, France
  • Research Site
    Marseille, France
  • Research Site
    Montpellier Cedex 5, France
  • Research Site
    Nice Cedex, France
  • Research Site
    Paris, France
  • Research Site
    Tours Cedex, France
  • Research Site
    Budapest, Hungary
  • Research Site
    Gyor, Hungary
  • Research Site
    Kecskemet, Hungary
  • Research Site
    Szeged, Hungary
  • Research Site
    Szolnok, Hungary
  • Research Site
    Bologna, BO, Italy
  • Research Site
    Cagliari, CA, Italy
  • Research Site
    Monserrato, CA, Italy
  • Research Site
    Kashiwa, Chiba, Italy
  • Research Site
    Firenze, FI, Italy
  • Research Site
    Genova, GE, Italy
  • Research Site
    Palermo, PA, Italy
  • Research Site
    Reggio Emilia, RE, Italy
  • Research Site
    Nagoya, Aichi, Japan
  • Research Site
    Matsuyama, Ehime, Japan
  • Research Site
    Kitakyusyu, Fukuoka, Japan
  • Research Site
    Ota, Gunma, Japan
  • Research Site
    Fukuyama, Hiroshima, Japan
  • Research Site
    Sapporo, Hokkaido, Japan
  • Research Site
    Amagasaki, Hyogo, Japan
  • Research Site
    Isehara, Kanagawa, Japan
  • Research Site
    Yokohama, Kanagawa, Japan
  • Research Site
    Osakasayama, Osaka, Japan
  • Research Site
    Suita, Osaka, Japan
  • Research Site
    Kitaadachi, Saitama, Japan
  • Research Site
    Chuo, Tokyo, Japan
  • Research Site
    Chiba, Japan
  • Research Site
    Fukuoka, Japan
  • Research Site
    Kumamoto, Japan
  • Research Site
    Niigata, Japan
  • Research Site
    Oita, Japan
  • Research Site
    Osaka, Japan
  • Research Site
    Den Haag, Netherlands
  • Research Site
    Nijmegen, Netherlands
  • Research Site
    Sittard, Netherlands
08

References and documents

Publications

  • Cataliotti L, Buzdar AU, Noguchi S, Bines J, Takatsuka Y, Petrakova K, Dube P, de Oliveira CT. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer. 2006 May 15;106(10):2095-103. doi: 10.1002/cncr.21872. PubMed 16598749 ↗
  • Fujiwara Y, Takatsuka Y, Imoto S, Inaji H, Ikeda T, Akiyama F, Tamura M, Miyoshi K, Iwata H, Mitsuyama S, Noguchi S. Outcomes of Japanese breast cancer patients treated with pre-operative and post-operative anastrozole or tamoxifen. Cancer Sci. 2012 Mar;103(3):491-6. doi: 10.1111/j.1349-7006.2011.02171.x. Epub 2012 Jan 13. PubMed 22136317 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2000, a primary completion of Jan 2003 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2005
First posted
Oct 5, 2005
Start
Aug 2000
Primary completionActual
Jan 2003
CompletionActual
Dec 2007
Last update
Feb 3, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00232661
Lead sponsor
AstraZeneca
First posted
Oct 5, 2005
Start date
Aug 2000
Primary completion
Jan 2003
Completion
Dec 2007
Last update
Feb 3, 2010

Study contacts

AstraZeneca Arimidex Medical Science Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anastrozole · Tamoxifen

Start the discussion